Product Description
LIDOCAINE (LYE doe kane) is an anesthetic. It causes loss of feeling in the skin and surrounding tissues. It is used to prevent and to treat pain from some procedures. This medicine is also used to treat minor burns, scrapes and insect bites. (Sourced from: https://my.clevelandclinic.org/health/drugs/19854-lidocaine-skin-cream-or-ointment)
Mechanisms of Action: Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous, Topical, Transdermal
FDA Designation: *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: ZARS Pharma
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Belgium, Canada, China, Czech Republic, France, Germany, Italy, Japan, Netherlands, Norway, Spain, United States
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Anesthesia Related|Cesarean Section|Collagen Diseases|Facial Nerve Diseases|Facial Pain|Injuries/wounds Unspecified|Intervertebral Disc Degeneration|Intestinal Diseases|Low Back Pain|Neuralgia, Postherpetic|Neuropathic Pain|Other|Pain Unspecified|Premature Ejaculation
Phase 2: Abdominal Pain|Anorexia|Chronic Pain|Hearing Loss, Bilateral|Ileus|Pelvic Pain
Phase 1: Diabetic Foot|Idiopathic Pulmonary Fibrosis|Lung Diseases, Interstitial|Progressive Pulmonary Fibrosis|Skin Ulcer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2023-504466-28-00 |
SENS-501-101 | P2 |
Recruiting |
Hearing Loss, Bilateral |
2030-12-31 |
2025-05-02 |
Treatments |
|
ACTRN12625001044415 |
ACTRN12625001044415 | P3 |
Not yet recruiting |
Neuralgia, Postherpetic |
2027-09-30 |
2025-09-23 |
Treatments |
|
NCT07076641 |
LIDORACHI | P3 |
Not yet recruiting |
Intestinal Diseases |
2027-07-30 |
5% |
2025-07-23 |
Primary Endpoints|Treatments |
NCT05923086 |
ORE001PIIPOI | P2 |
Recruiting |
Ileus |
2025-12-31 |
35% |
2024-10-04 |
Primary Completion Date|Primary Endpoints |
CTR20254425 |
CTR20254425 | P1 |
Completed |
Premature Ejaculation |
2025-12-15 |
2026-01-18 |
||
NCT05707208 |
ST-CP-202 | P2 |
Active, not recruiting |
Chronic Pain |
2025-12-04 |
2% |
2025-12-03 |
Primary Endpoints |
2023-510499-30-00 |
OREPhIIAnorexia | P2 |
Not yet recruiting |
Anorexia |
2025-06-30 |
2025-05-02 |
Treatments |
|
2023-508224-35-01 |
2023-508224-35-01 | P2 |
Recruiting |
Abdominal Pain|Chronic Pain |
2025-03-31 |
2025-05-02 |
Treatments |
|
NCT05921292 |
OM-CTP-002 | P1 |
Completed |
Skin Ulcer |
2024-01-22 |
2024-06-28 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2021-006632-67 |
QETAL | P3 |
Active, not recruiting |
Anesthesia Related|Cesarean Section |
2023-09-08 |
|||
ACTRN12621000589886 |
ACTRN12621000589886 | P2 |
Recruiting |
Pelvic Pain|Chronic Pain |
2023-12-29 |
2024-08-29 |
Treatments |
|
CTR20212038 |
CTR20212038 | P3 |
Completed |
Neuropathic Pain |
2023-11-30 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
NCT05088980 |
NCT05088980 | P3 |
Completed |
Other |
2023-11-29 |
10% |
2023-12-21 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05417425 |
OM-CTP-003.1 | P1 |
Completed |
Diabetic Foot |
2023-10-31 |
2024-06-07 |
Primary Endpoints |
|
NCT05793892 |
CU-30101-304 | P3 |
Completed |
Facial Pain|Anesthesia Related|Collagen Diseases|Facial Nerve Diseases |
2023-08-23 |
30% |
2024-11-13 |
Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |
NCT03737461 |
RESPINE | P3 |
Active, not recruiting |
Intervertebral Disc Degeneration|Low Back Pain |
2022-05-30 |
27% |
2023-08-15 |
|
ACTRN12620001141932p |
SPPH | P1 |
Not yet recruiting |
Progressive Pulmonary Fibrosis|Lung Diseases, Interstitial|Idiopathic Pulmonary Fibrosis |
2021-01-22 |
|||
2015-002160-17 |
2015-002160-17 | P3 |
Active, not recruiting |
Pain Unspecified|Injuries/wounds Unspecified |
2017-12-24 |
2022-03-13 |
Treatments |
|
2023-507633-21-00 |
MN45053 | P3 |
Withdrawn |
Unknown |
2029-07-31 |
2025-05-02 |
Treatments |
|
CTR20253835 |
CTR20253835 | P1 |
Completed |
Premature Ejaculation |
2025-12-12 |
2025-12-21 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20250271 |
CTR20250271 | P3 |
Completed |
Premature Ejaculation |
2025-11-18 |
2026-01-11 |
||
CTR20253834 |
CTR20253834 | P1 |
Completed |
Premature Ejaculation |
2025-11-11 |
2026-01-04 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20254137 |
CTR20254137 | P1 |
Completed |
Premature Ejaculation |
2025-11-11 |
2025-12-06 |
Primary Completion Date |
|
CTR20252515 |
CTR20252515 | P1 |
Completed |
Premature Ejaculation |
2025-09-09 |
2025-10-05 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
CTR20252536 |
CTR20252536 | P1 |
Completed |
Premature Ejaculation |
2025-08-06 |
2025-09-07 |
Primary Completion Date|Study Completion Date|Treatments|Trial Status |